Primary PCI for STEMI, STEMI (STE-ACS)
Conditions
Keywords
Atorvastatin, hs-CRP, Albumin, TIMI Thrombus Grade, Thrombus Burden
Brief summary
40 STEMI patients who underwent primary PCI were subsequently allocated into two groups via a double-blind randomization method: An Atorvastatin 80 mg group and the control group. Levels of hs-CRP and albumin were assessed for both groups upon presentation at the emergency department before to initial PCI and were re-evaluated 24 hours after primary PCI. Thrombus burden was assessed using angiography with the TIMI Thrombus grade.
Detailed description
This study encompasses 40 STEMI patients who underwent primary PCI at Dr. Moewardi General Hospital in Central Java, Indonesia, between September and October. This study employed an experimental design with a pre-and-post technique, with participants recruited through sequential sampling. Patients were subsequently allocated into two groups via a double-blind randomization method. A treatment group was administered a loading dose of high-intensity statin (80 mg atorvastatin) upon initial presentation at the emergency department (ED), whereas the control group received no such intervention. Both cohorts received therapy in accordance with established guidelines prior to performing primary PCI. Levels of hs-CRP and albumin were assessed for both groups upon presentation at the emergency department before to initial PCI. In the treatment group, a second 80 mg dose of atorvastatin was provided 24 hours after the original dose. Both hs-CRP and albumin levels were re-evaluated 24 hours after primary PCI in both the control and treatment cohorts. Thrombus burden was assessed using angiography with the TIMI Thrombus grade
Interventions
DRUGAtorvastatin 80mg
80 mg of Atorvastatin are loading in first medical contact (Emergency Department) before primary PCI
DRUGPlacebo
Only given a loading DAPT without loading Atorvastatin 80 mg
Sponsors
Universitas Sebelas Maret
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Investigator)
Intervention model description
40 STEMI patients undergoing primary PCI at Dr. Moewardi General Hospital participated in this experimental investigation. Using a double-blind technique, subjects were randomized into two groups: one receiving 80 mg of atorvastatin and the other's don't. Prior to and following primary PCI, levels of albumin and hs-CRP were assessed also their correlation with TIMI Thrombus Grade.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* STEMI with onset less than 24 hour and undergo a Primary PCI
Exclusion criteria
* STEMI beyond 24 hours from the onset of chest pain * Prior statin therapy within the preceding 24 hours * Hypersensitivity to statins, pregnancy, lactation, severe inflammatory conditions including active liver dysfunction, chronic kidney disease (eGFR \<30 mL/min), autoimmune disorders, malignancy, severe malnutrition, and * Contraindications to statin administration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hs-CRP/Albumin ratio | From enrollment to the end of treatment at 3 days | The administration of 80 mg atorvastatin significantly reducing the hs-CRP/Albumin ratio (Δ 0.35 ± 0.67; p \< 0.001) if compared to the control group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| TIMI Thrombus Burden | From enrollment to door to balloon time (Less than 24 hour onset) | Using a TIMI Thrombus Burden that measure while performing PCI, we analyze that High burden thrombus was correlated with elevated of hs-CRP/Albumin ratio (r = 0.562; p = 0.012; r \> 0.05; p \< 0.05). So, by reducing Hs-CRP/Albumin Ratio, it appears also reducing the TIMI Thrombus burden. |
Countries
Indonesia
Outcome results
None listed